Associated Papers
In vitro characterization of SLCO2B1 genetic variants.
Sinokki A et al.
Journal of Pharmaceutical Sciences, 2025
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.
Kim TE et al.
Basic & Clinical Pharmacology & Toxicology, 2017
Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition.
Zhou F et al.
Advanced Drug Delivery Reviews, 2017
Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups.
Namgoong S et al.
Environmental Toxicology and Pharmacology, 2015
Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans.
Kim KA et al.
Journal of Clinical Pharmacology, 2013
SLCO2B1 genetic polymorphisms in a Korean population: pyrosequencing analyses and comprehensive comparison with other populations.
Kim KA et al.
Molecular Biology Reports, 2013
SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
Tapaninen T et al.
Pharmacogenetics and Genomics, 2013
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1.
Nies AT et al.
Genome Medicine, 2013
Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms.
König J
Handbook of Experimental Pharmacology, 2011
Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Akamine Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2010
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C et al.
Drug Metabolism Reviews, 2010
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members.
Seithel A et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Implications of genetic polymorphisms in drug transporters for pharmacotherapy.
Kerb R
Cancer Letters, 2006
Pharmacogenomics of human OATP transporters.
König J et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2006
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
Niemi M et al.
Pharmacogenetics, 2004
Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis.
Nozawa T et al.
The Journal of Pharmacology and Experimental Therapeutics, 2002